Verruca Vulgaris--Skin Test &Candida /Mumps Antigen

$0M01FY2000RRNIH

University Of Arkansas Med Scis Ltl Rock, Little Rock AR

Investigators

Linked publications & trials

Paper 35099792 Paper 28595173 Paper 28366517 Paper 25294621 Paper 25122628 Paper 23902932 Paper 23724137 Paper 23673729 Paper 22841544 Paper 22651256 Paper 22617163 Paper 22437669 Paper 22108096 Paper 22068385 Paper 21994960 Paper 21983869 Paper 21688350 Paper 21593104 Paper 21481745 Paper 21314643 Paper 21129760 Paper 21084393 Paper 20960272 Paper 20952514 Paper 20943786 Paper 20841504 Paper 20592451 Paper 20392866 Paper 20097709 Paper 20078008 Paper 20043249 Paper 19808853 Paper 19667111 Paper 19617235 Paper 19564324 Paper 19435833 Paper 19389826 Paper 19366958 Paper 19336660 Paper 19324371 Paper 19255007 Paper 19247271 Paper 19196080 Paper 19141583 Paper 19056637 Paper 19032037 Paper 18996869 Paper 18948558 Paper 18940392 Paper 18728164 Paper 18697866 Paper 18544642 Paper 18510435 Paper 18366646 Paper 18274270 Paper 18214850 Paper 18214849 Paper 18200815 Paper 18166691 Paper 18165829 Paper 18073271 Paper 18057090 Paper 17901242 Paper 17878257 Paper 17670860 Paper 17595259 Paper 17585023 Paper 17579832 Paper 17563344 Paper 17495878 Paper 17456818 Paper 17398176 Paper 17327457 Paper 17317272 Paper 17233681 Paper 17199713 Paper 17185765 Paper 17174134 Paper 17130488 Paper 17090638 Paper 17079360 Paper 17003361 Paper 17003347 Paper 16968813 Paper 16936214 Paper 16936202 Paper 16900012 Paper 16895887 Paper 16894240 Paper 16803857 Paper 16799131 Paper 16567381 Paper 16540829 Paper 16520030 Paper 16497530 Paper 16490437 Paper 16457979 Paper 16432272 Paper 16309379 Paper 16260965

Abstract

Although there are many treatment options available for verruca vulgaris (VV), it is difficult to achieve a lasting response. Recurrence rates ranging from 5% to 56% have been reported in the literature. In an effort to lower recurrence rates and optimize treatment for recalcitrant VV, we are pursuing an immunotherapeutic approach that takes advantage of the prior sensitization to candida and mumps prevalent in the population. We hypothesize that VV can be successfully treated wtih immunotherapy by eliciting a local response in patients with delayed type hypersensitivity (DTH) reactions to candida or mumps antigen.

View original record on NIH RePORTER →